Please provide your email address to receive an email when new articles are posted on . Most participants achieved IGF-1 control and reduced acromegaly symptoms at 1 year with CAM2029. Improvements in ...

Please provide your email address to receive an email when new articles are posted on . Most adults with acromegaly maintained or improved IGF-I levels with oral octreotide in three phase 3 trials.

Researchers at the Medical University of South Carolina revealed the need to clarify current treatment guidelines for octreotide therapy following an esophageal variceal hemorrhage in a recent study ...

October 12, 2012 (Montreal, Quebec) — In a finding described as both surprising and practice-changing, octreotide (Sandostatin, Novartis) showed no benefit over less expensive, more accessible ...

May 29, 2012 (Florence, Italy) — In patients with acromegaly, long-acting-release (LAR) pasireotide (SOM230, Novartis) was more effective than octreotide LAR (Sandostatin, Novartis) at inducing ...

The FDA issued a complete response letter to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its treatment for the hormonal disorder acromegaly to market because of problems ...

Significant increases in biochemical response rates were observed in the overall population and in new patients. Treatment with CAM2029, an investigational once-monthly octreotide subcutaneous (SC) ...